Drug discovery and treatment paradigms in nonalcoholic steatohepatitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis

Published:2019-12-10 Issue:4 Volume:3 Page:
ISSN:2398-9238
Container-title:Endocrinology, Diabetes & Metabolism
language:en
Short-container-title:Endocrinol Diab Metab

Author:

Noureddin Mazen¹,Muthiah Mark D.²³^ORCID,Sanyal Arun J.⁴

Affiliation:

1. Division of Digestive and Liver Diseases Comprehensive Transplant Center Cedars Sinai Medical Center Los Angeles California

2. Department of Medicine Yong Loo Lin School of Medicine National University of Singapore Singapore

3. Division of Gastroenterology and Hepatology National University HospitalNational University Health System Singapore

4. Division of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University School of Medicine Richmond Virginia

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/edm2.105

Reference130 articles.

1. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

2. Therapies in non-alcoholic steatohepatitis (NASH)

3. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

4. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease

5. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Root Extract of Rosa multiflora Ameliorates Nonalcoholic Steatohepatitis Development via Blockade of De Novo Lipogenesis and Inflammation;Current Issues in Molecular Biology;2024-06-12

2. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population;Diabetes Research and Clinical Practice;2024-05

3. MASH clinical trials and drugs pipeline: An impending tsunami;Hepatology;2024-03-19

4. Characteristics of contemporary drug clinical trials regarding the treatment of non-alcoholic steatohepatitis;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2024-01

5. A scientifically validated combination of garcinol, curcuminoids, and piperine for mild to moderate nonalcoholic steatohepatitis patients—results from a randomized, double-blind, placebo-controlled study;Frontiers in Nutrition;2023-12-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3